Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Oct 9 · above the Ichimoku cloud · RSI 53 · MACD below its signal · 3% above its 52-week low
None of the 29 investors followed here reported a position in OACCU in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a OACCU trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for OACCU.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.8 | -1.1 | 0.0 | 0.0 | 2.9 | 0.1 | -0.0 | 0.0 | 0.0 | 0.0 | +2.7% | ||
| 2025 | 0.5 | -0.6 | 3.2 | 0.1 | 1.1 | 0.5 | 0.0 | -0.4 | 0.8 | 0.2 | 2.6 | -2.2 | +5.7% |
| 2024 | 1.0 | 0.3 | +1.3% |
No analyst coverage for this instrument.
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was founded in 1995 and is headquartered in Los Angeles, California.
No recent headlines.